

Date: 11th February-2026

GLOBAL PREVALENCE OF CHRONIC KIDNEY DISEASE, THE
IMPORTANCE OF LABORATORY INDICATORS IN EARLY DETECTION,
AND PREVENTION STRATEGIES

I.Ibragimov

Central Asian Medical University

Clinical residency

Abstract Chronic kidney disease (CKD) is a growing global health challenge with significant morbidity and mortality. CKD affects more than 10 % of the world's population, and its prevalence continues to increase due to aging populations and rising rates of diabetes mellitus and hypertension. Because early CKD is often asymptomatic, delayed detection can lead to irreversible disease progression and serious complications. Laboratory biomarkers are essential for early diagnosis and risk stratification, thus enabling prompt intervention and effective preventive strategies. This article reviews current global prevalence data, the role of key laboratory markers including estimated glomerular filtration rate (eGFR), albuminuria, and emerging biomarkers, and discusses evidence-based prevention approaches.

Keywords: chronic kidney disease, early diagnosis, laboratory biomarkers, eGFR, albuminuria, cystatin C

Introduction

Chronic kidney disease (CKD) represents a major public health concern worldwide. Recent global estimates suggest that **between 700 million and 850 million people are affected by CKD**, with a prevalence exceeding 10 % of the adult population. CKD may surpass common chronic diseases in prevalence yet remains underdiagnosed due to its silent early course and varied screening practices. [1,2,3,4,5,6]

CKD's asymptomatic nature during early stages, combined with low awareness and inadequate screening programs, contributes to late presentation and increased disease burden. Globally, CKD ranks among the leading causes of death and disability, with projections indicating rising mortality if detection and prevention measures are not improved. [7,8,9,10,11]

Global Prevalence and Epidemiology

Systematic reviews indicate that **general population prevalence of CKD stages 1–5 is approximately 13.4 %**, and stages 3–5 at around 10.6 %, with variations depending on region, age, and risk factors. [12,13,14,15]

Epidemiological studies also show variability across countries and settings. Targeted screening among high-risk populations often reveals higher detection rates than general population screening. For example, CKD detection rates are significantly higher in people with diabetes or hypertension compared with unselected populations.



Date: 11thFebruary-2026

Despite this high global prevalence, **a large portion of CKD remains undiagnosed or underrecognized**, especially in low- and middle-income countries where screening and early identification efforts are limited. [16,17,18,19,20]

Importance of Early Detection Using Laboratory Indicators

Effective laboratory screening plays a central role in identifying CKD before progression to advanced stages. Early detection enables clinicians to implement timely interventions that reduce progression to end-stage kidney disease and associated complications.[21,22,23,24,25]

1. Serum Creatinine and Estimated Glomerular Filtration Rate (eGFR)

Serum creatinine measurement and eGFR estimation remain the backbone of CKD diagnosis. eGFR reliably reflects kidney filtration function and is used to stage CKD. Persistent **eGFR < 60 mL/min/1.73 m² for at least 3 months** is a diagnostic criterion for CKD. [26,27,28,29,30]

2. Albuminuria and Urine Tests

Albuminuria, typically assessed through the urine albumin-to-creatinine ratio (UACR), is an early indicator of kidney damage, especially in diabetic and hypertensive patients. Regular monitoring of albuminuria is recommended for high-risk individuals to facilitate early detection.[31,32,33,34]

3. Emerging Biomarkers

Beyond traditional markers, **emerging biomarkers**—such as cystatin C, neutrophil gelatinase-associated lipocalin (NGAL), and kidney injury molecule-1 (KIM-1)—hold promise for earlier and more sensitive CKD detection, especially during subclinical kidney injury. These novel markers may improve prediction and risk stratification but require further validation for routine clinical use. [35,36,37,38]

Screening Strategies and Clinical Significance

CKD often progresses silently, making routine laboratory screening essential, particularly in high-risk groups such as individuals with diabetes, hypertension, cardiovascular disease, or family history of kidney disease. Targeted screening has shown higher diagnostic yield than population-based screening alone. [39,40]

International nephrology bodies also emphasize the need for consistent screening programs and improved access to laboratory diagnostics to promote early CKD identification and reduce the burden of advanced disease.[41]

Prevention and Risk Reduction

Primary and secondary prevention strategies for CKD include:

Control of major risk factors: Effective management of hypertension, diabetes, and obesity is crucial in reducing the risk and progression of CKD.

Healthy lifestyle promotion: Diet modification, physical activity, and avoidance of nephrotoxic substances help mitigate CKD risk.

Patient education and awareness: Increasing public and clinical awareness about CKD and its asymptomatic nature can improve early diagnosis rates.

Routine laboratory monitoring: Periodic assessment of eGFR and albuminuria in at-risk populations enables early intervention.



Date: 11thFebruary-2026

These measures collectively contribute to reducing CKD incidence, slowing disease progression, and minimizing cardiovascular and renal complications.

Conclusion

Chronic kidney disease poses a significant global health burden, with a high prevalence that is likely underestimated due to inadequate early detection. Laboratory markers, including eGFR, albuminuria, and emerging biomarkers, play an indispensable role in early CKD diagnosis. Evidence-based screening targeting high-risk populations, combined with preventive strategies and risk factor management, can substantially reduce disease progression and improve patient outcomes. Strengthening global screening policies and expanding access to laboratory diagnostics are essential steps toward reducing the worldwide impact of CKD.

REFERENCES:

- 1.GBD 2021 Chronic Kidney Disease collaborative study; global burden of chronic kidney disease and its underlying causes. *BMC Public Health*. 2025.
- 2.Kidney disease and the global public health agenda: an international consensus. *Nature Reviews Nephrology*. 2025.
- 3.Global prevalence of chronic kidney disease: systematic review and meta-analysis. *PMC*. 2016.
- 4.Early identification of CKD — global populations scoping review. *PMC*. 2022.
- 5.Chronic Kidney Disease screening led by community pharmacists; point-of-care eGFR screening study. *Scientific Reports*. 2024.
- 6.Emerging biomarkers for early detection of chronic kidney disease. *J Pers Med*. 2022.
- 7.Approaches to CKD identification and screening in low- and middle-income countries. *PMC*. 2020.
8. M Abdullayeva, U Makhamatov /EARLY DETECTION OF IRON DEFICIENCY IN WOMEN OF CHILDREN. AMERICAN JOURNAL OF APPLIED MEDICAL SCIENCE 4 (1), 209-214
9. U Khatamova, U Makhamatov /DIAGNOSTIC AND PROGNOSTIC MARKERS OF LEUKEMIA DURING HEMATOLOGICAL ANALYZER EXAMINATION: LABORATORY ANALYSIS OF LEUKEMIA MARKERS AMERICAN JOURNAL OF APPLIED MEDICAL SCIENCE 4 (1), 215-221
10. A Kholmatov, U Makhamatov/ BLOOD PLASMA PROTEIN FRACTIONS AND IMMUNOFIXATION IN MYELOMA DISEASE—IMMUNO-LABORATORY ANALYSIS AMERICAN JOURNAL OF APPLIED MEDICAL SCIENCE 4 (1), 222-227
11. Makhamatov, U., Malikov, N., Po‘latov, S., Yusupov, M., Ibragimov, U., Kenjayeva, X., & Umarov, S. (2026). ORGANIZING HEALTHY AND SAFE NUTRITION IN NON-COMMUNICABLE DISEASES. *Shokh Articles Library*, 1(1).
- 12.SOG‘LOM TURMUSH TARZINI TASHKIL ETISHNI DOLZARB MUAMMOLARI VA ULARNING YECHIMLARI. M .Ashurova, U Maxamatov, X Xaitov, S Yakubov, U



Date: 11th February-2026

Ibragimov. SCIENTIFIC ASPECTS AND TRENDS IN THE FIELD OF SCIENTIFIC RESEARCH 3 (33), 57-61

13. Flatulence in Children and Adolescents and its Prevention. U Shoirjonovich, KM Abdulkhamidovna. European Journal of Innovation in Nonformal Education 2 (1), 83-85

14. Its Importance for The Health of the Child and Mother. HA Akhunjonova, US Makhamatov, KM Saydullayeva, KO Khojimatov, ...Journal of clinical and preventive medicine 2, 61-64

15. HISTOSTRUCTURE OF THE GASTRIC MUCOUS MEMBRANE OF RATS WITH A SINGLE PROTEIN DIET. S Salomov, XM Aliyev, PP Rakhmanov, MD Ashurova, US Makhamatov. EUROPEAN JOURNAL OF MODERN MEDICINE AND PRACTICE 2 (4), 14-16

16. Platelet deficiency disease among children and adolescents and measures to prevent it. KMA Makhamatov U.Sh. Eurasian Medical Research Periodical, 37-39

17. Food Poisoning and Its Prevention and Disposal Methods. XU Baxodirovna, MU Shoirjonovich. Мировая наука, 85-87

18. Negative Consequences of Poor and Irregular Diet and Recommendations for Healthy Diet. MD Ashurova, US Maxamatov, UA Teshaboyev, KM Saydullayeva
Ethiopian International Journal of Multidisciplinary Research 10 (11), 509-512

19. Integral Helmitoses in Children and Their Etiological Factors. U Maxamatov, M Xabibullayeva. IQRO JURNALI 1 (2), 233-236

20. CLINIC, DIAGNOSIS OF BOTULISM IN CHILDREN AND ADOLESCENTS OF SCHOOL AGE MUS COURSE. World Bulletin of Public Health 18, 50-52

21. Nutrition of Young Mothers and Recommendations. U Maxamatov, A Nematullayev, D Raimjonov, J Ikromov. Eurasian Journal of Medical and Natural Sciences 2 (6), 160-162

22. Negative Consequences of More Eating and Recommendations on Eating
U Maxamatov, D Raimjonov, J Ikromov, A Nematullayev

Евразийский журнал медицинских и естественных наук 2 (6), 156-159

23. THE EFFECTIVENESS OF URGENT MEDICAL INSTRUCTIONS IN EMERGENCY STATIONS. MU Shoirjonovich, XU Baxodirovna
Мировая наука, 37-40

24. Determining the health of children and adolescents. M.D. Ashurova, U.Sh. Makhamatov, K.M. Saydullaeva, A.L Valiyev, F.I Isroilov. BIO Web of Conferences 65, 05029

25. THE PLACE AND ROLE OF HEALTHY AND HIGH-QUALITY NUTRITION IN STUDENTS' MASTERY OF EDUCATIONAL ACTIVITIES

MD Ashurova. Ethiopian International Journal of Multidisciplinary Research 10 (11), 506-508

26. Anemia Disease and Rational Nutrition in it. U Makhamatov IQRO 2 (2), 280-283

27. Gigenic Bases of Optimization of Children and Comments Nursed in General Schools. U Maxamatov. Web of Semantic: Universal Journal on Innovative Education 2 (3), 56-65

28. Treatment of Triggeral Helmitosis in Children and Adolescents Using Folk Medicine. U.Sh. Maxamatov. Univer Publishing



Date: 11th February-2026

29. Анализ пациентов с инфекцией COVID-19, роль микроэлемента цинка в организме человека и его роль в распространении и профилактике заболевания. УА Тешабоев, ХК Рузматова, УШ Махаматов, КМ Сайдуллаева
Экономика и социум, 374-381
30. Vitamins and Human health. UB Xatamova, US Maxamatov. Мирская наука, 83-85
31. OPTIMAL NUTRITION PROGRAM FOR CHILDREN: DEVELOPMENT AND IMPLEMENTATION. M Umidjon Modern World Education: New Age Problems–New solutions 1 (3), 70-72
32. ОЖИРЕНИЕ И ЕГО ПОСЛЕДСТВИЯ. У Махаматов Научный Импульс 3 (26), 69-73
33. EKSTRAGENITAL PATOLOGIYALAR, HOMILADORLIKNING O‘ZARO BIR BIRIGA TA’SIRI VA BU HOLATDA OVQATLANISH TARTIBI
U Maxamatov, D Abselyamov, X Kenjayeva, S Po‘latov. MASTERS 3 (3), 5-10
34. CARDIOVASCULAR DISEASES AND HYGIENIC PRINCIPLES OF HEALTHY NUTRITION. F Mamadaliyev, D Abselyamov, S Pulatov, K Kenjayeva, U Maxamatov. Journal of Multidisciplinary Sciences and Innovations 1 (2), 765-768
35. EMERGENCY SITUATIONS RESPONSIBILITIES AND PREVENTION MEASURES. MU Shoirjonovich, XU Ваходировна. Мирская наука, 33-36
36. РАЗВИТИЕ ДИАБЕТА У БОЛЬНЫХ ИНФЕКЦИЕЙ COVID-19//Евразийский журнал медицинских и естественных наук.–2022
УШ Махаматов. Т 2 (5), 13-18
37. СТАНОВЛЕНИЕ МИКРОБИОЦЕНОЗА У НЕДОНОШЕННЫХ И НОРМАЛЬНОРОЖДЕННЫХ НОВОРОЖДЕННЫХ ДЕТЕЙ
РМ Шерматов, УШ Махаматов. Актуальные научные исследования в современном мире, 76-79
38. METABOLISM OF BASIC SUBSTANCES AND THEIR SIGNIFICANCE IN THE BODY. U Maxamatov, D Abselyamov. MODELS AND METHODS FOR INCREASING THE EFFICIENCY OF INNOVATIVE RESEARCH 4
39. Makhamatov U., Muslimakhon R. THE ROLE OF UNHEALTHY DIET IN THE PATHOGENESIS OF NON-COMMUNICABLE DISEASES //AMERICAN JOURNAL OF APPLIED MEDICAL SCIENCE. – 2025. – Т. 3. – №. 10. – С. 63-72.
40. Makhamatov U., Muslimakhon R. NUTRITION OPTIMIZATION IN OSTEOPOROSIS FOLLOWING COVID-19 //AMERICAN JOURNAL OF APPLIED MEDICAL SCIENCE. – 2025. – Т. 3. – №. 10. – С. 52-62.
41. Maxamatov U., Muslimaxon R. SOG‘LOM TURMUSH TARZI SALOMATLIK OMILI //AMERICAN JOURNAL OF APPLIED MEDICAL SCIENCE. – 2025. – Т. 3. – №. 10. – С. 73-82.

